Pfizer (PFE)
(Delayed Data from NYSE)
$29.09 USD
+0.12 (0.41%)
Updated Sep 27, 2024 04:02 PM ET
After-Market: $29.09 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.09 USD
+0.12 (0.41%)
Updated Sep 27, 2024 04:02 PM ET
After-Market: $29.09 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
Zacks News
WHO Recommends Merck (MRK) Oral Pill for Certain COVID Patients
by Ekta Bagri
Merck's (MRK) and Ridgeback Biotherapeutics' oral antiviral drug molnupiravir has been included in the treatment guidelines for COVID-19 by WHO.
Pfizer (PFE) Gets Breakthrough Therapy Status for RSV Vaccine
by Zacks Equity Research
Pfizer (PFE) is developing an RSV vaccine candidate, RSVpreF, to immunize pregnant women or older adults. The FDA grants a breakthrough therapy tag for the candidate's use in pregnant women.
Novavax's (NVAX) Q4 Loss Wider Than Expected, 2022 View Weak
by Zacks Equity Research
Novavax (NVAX) reports a wider-than-expected loss for the fourth quarter of 2021. Also, revenues miss estimates. Its shares decline in after-market trading following the announcement.
Nektar (NKTR) Q4 Earnings Top, Three Bempeg Filings Due in 2022
by Zacks Equity Research
Nektar (NKTR) reports mixed fourth-quarter 2021 results. The company remains on track to report top-line data from three registrational studies on bempegaldesleukin in the first half of 2022.
Biohaven's (BHVN) Q4 Earnings Miss, Nurtec Gets CHMP Nod
by Zacks Equity Research
Biohaven's (BHVN) sole approved drug, Nurtec ODT, for treating migraine, continues to demonstrate strong demand in the United States. The CHMP recommends approval of Nurtec ODT. Stock declines.
Should Schwab U.S. Dividend Equity ETF (SCHD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SCHD
Ionis (IONS) Q4 Earnings & Revenues Beat Estimates, Stock Up
by Zacks Equity Research
Teaser: Ionis (IONS) beats Q4 earnings and sales estimates. Stock rises.
Should You Invest in the Vanguard Health Care ETF (VHT)?
by Zacks Equity Research
Sector ETF report for VHT
Arena (ARNA) Q4 Loss Wider Than Expected, Etrasimod in Focus
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) misses on Q4 bottom line. Top-line data from several phase III studies on etrasimod are slated for release in 2022.
Should WisdomTree U.S. High Dividend ETF (DHS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DHS
Exelixis (EXEL) Q4 Earnings & Revenues Beat, Cabometyx Strong
by Zacks Equity Research
Exelixis (EXEL) beats on both earnings and revenues in the fourth quarter. Both figures increase on a year-over-year basis.
Pharma Stock Roundup: EU Approval to PFE, AZN Products, FDA Nod to LLY New COVID Drug
by Kinjel Shah
FDA grants EUA to Eli Lilly's (LLY) new COVID antibody-drug, bebtelovimab. AstraZeneca's (AZN) Saphnelo and Pfizer's (PFE) Ngenla (somatrogon) and Apexxnar vaccine get approval in Europe
Pfizer (PFE) Gets EU Nod for Somatrogon & Pneumococcal Jab
by Zacks Equity Research
Pfizer (PFE) gets approval for pediatric growth hormone deficiency drug, Ngenla (somatrogon) and 20-valent pneumococcal conjugate vaccine, Apexxnar, in Europe.
OPKO's (OPK) NGENLA to Offer GHD Treatment in European Union
by Zacks Equity Research
OPKO's (OPK) marketing authorization for NGENLA in the European Union stands to benefit children and adolescents affected by growth hormone deficiency.
Should Value Investors Pick Pfizer (PFE) Stock For Now?
by Zacks Equity Research
Is Pfizer (PFE) a great pick from the value investor's perspective right now? Read on to know more.
Biohaven (BHVN) Migraine Drug Meets Study Goals in China
by Zacks Equity Research
Biohaven (BHVN) and partner Pfizer announce positive top-line results from a phase III study on rimegepant for the acute treatment of migraine. The study meets the co-primary endpoints.
Pfizer (PFE) to Ride on COVID Jab & Pill in 2022: What Next?
by Kinjel Shah
Pfizer's (PFE) COVID-19 vaccine and its oral antiviral pill for COVID-19, Paxlovid are expected to generate a combined $54 billion in sales in 2022.
Zacks.com featured highlights include: Pfizer, Teck Resources, NXP Semiconductors, Equinor and KB Home
by Zacks Equity Research
Pfizer, Teck Resources, NXP Semiconductors, Equinor and KB Home are highlighted in this Screen of the Week article.
Lilly's (LLY) COVID-19 Drug Gets FDA Nod for Emergency Use
by Zacks Equity Research
Lilly's (LLY) new antibody-drug, bebtelovimab is authorized to treat certain non-hospitalized adults and pediatric patients with mild-to-moderate COVID-19 who are at high risk of progressing to severe disease
Are Investors Undervaluing These Medical Stocks Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Pfizer (PFE) Plans to Delay Comirnaty for Kids EUA Submission
by Zacks Equity Research
Pfizer (PFE) and its partner BioNTech are planning to extend their rolling submission to the FDA for the authorization of Comirnaty for use in children 6 months through 4 years of age to include the three-dose data.
5 Lucrative GARP Stocks With Discounted PEG
by Urmimala Biswas
Here are the stocks, PFE, TECL, NXPI, EQNR and KBH based on discounted PEG.
Should Invesco S&P Ultra Dividend Revenue ETF (RDIV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for RDIV
The Zacks Analyst Blog Highlights: Pfizer, AstraZeneca, Glaxo, Sanofi's and Eli Lilly
by Zacks Equity Research
Pfizer, AstraZeneca, Glaxo, Sanofi¿¿¿s and Eli Lilly are highlighted in this Analyst Blog.
The Zacks Analyst Blog Highlights: Pfizer Inc., Texas Instruments Inc., Packaging Corp. of America, Atmos Energy Corp. and Crown Castle International Corp
by Zacks Equity Research
Pfizer Inc., Texas Instruments Inc., Packaging Corp. of America, Atmos Energy Corp. and Crown Castle International Corp. are highlighted in this Analyst Blog.